RegeneRx

Shareholder letter - Thursday May 22, 2014

Link to document.


RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

July 15, 2014
New Report: Thymosin β4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice


July 7, 2014
RegeneRx’s Strategic Partner G-treeBNT Preparing for Phase III Dry Eye Trials in Asia with RGN-259


June 23, 2014
Chinese FDA Accepts Phase 2 IND for RGN-259 for Dry Eye


June 10, 2014
RegeneRx Chairman, Dr. Allan L. Goldstein, to Speak at Major Drug Industry Conference


May 22, 2014
RegeneRx Issues Letter to Shareholders


April 21, 2014
RegeneRx Receives Notice of Allowance for U.S. Patent for Treatment of Stroke


March 28, 2014
RegeneRx Receives $1.35 Million Pursuant to Product License And Stock Purchase Agreement